| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Hepatocellular | 87 | 2025 | 938 | 17.390 |
Why?
|
| Liver Cirrhosis | 90 | 2025 | 834 | 17.010 |
Why?
|
| Liver Neoplasms | 89 | 2025 | 1318 | 15.660 |
Why?
|
| Hepatitis C, Chronic | 54 | 2025 | 324 | 14.580 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 48 | 2025 | 397 | 14.450 |
Why?
|
| Hepatitis C | 40 | 2023 | 364 | 9.530 |
Why?
|
| Antiviral Agents | 50 | 2025 | 746 | 9.010 |
Why?
|
| Gastroenterology | 16 | 2022 | 191 | 7.090 |
Why?
|
| Liver Transplantation | 35 | 2024 | 1038 | 5.270 |
Why?
|
| Hepatitis B, Chronic | 16 | 2024 | 82 | 4.810 |
Why?
|
| Liver Diseases | 17 | 2024 | 366 | 3.910 |
Why?
|
| End Stage Liver Disease | 13 | 2024 | 182 | 3.840 |
Why?
|
| Veterans | 31 | 2024 | 1757 | 3.610 |
Why?
|
| Liver Diseases, Alcoholic | 7 | 2023 | 57 | 3.450 |
Why?
|
| Acute-On-Chronic Liver Failure | 7 | 2023 | 64 | 3.440 |
Why?
|
| United States | 108 | 2025 | 10821 | 3.430 |
Why?
|
| Hepacivirus | 24 | 2023 | 241 | 3.160 |
Why?
|
| Humans | 290 | 2025 | 124482 | 3.030 |
Why?
|
| Quality Indicators, Health Care | 14 | 2024 | 218 | 2.860 |
Why?
|
| Middle Aged | 126 | 2025 | 26511 | 2.720 |
Why?
|
| Fatty Liver | 8 | 2024 | 183 | 2.680 |
Why?
|
| United States Department of Veterans Affairs | 26 | 2024 | 671 | 2.480 |
Why?
|
| Epidemics | 4 | 2021 | 54 | 2.350 |
Why?
|
| Risk Factors | 62 | 2025 | 10181 | 2.260 |
Why?
|
| Healthcare Disparities | 5 | 2023 | 430 | 2.230 |
Why?
|
| Mass Screening | 13 | 2024 | 784 | 2.210 |
Why?
|
| Risk Assessment | 30 | 2024 | 3392 | 2.150 |
Why?
|
| Retrospective Studies | 76 | 2024 | 16270 | 2.100 |
Why?
|
| Male | 141 | 2025 | 61053 | 2.060 |
Why?
|
| Early Detection of Cancer | 11 | 2024 | 359 | 2.030 |
Why?
|
| Aged | 80 | 2025 | 19549 | 2.010 |
Why?
|
| Pancreatic Neoplasms | 8 | 2023 | 686 | 1.990 |
Why?
|
| Primary Health Care | 9 | 2025 | 774 | 1.960 |
Why?
|
| Cost of Illness | 9 | 2023 | 247 | 1.950 |
Why?
|
| Female | 131 | 2025 | 66319 | 1.830 |
Why?
|
| Esophageal and Gastric Varices | 5 | 2023 | 64 | 1.770 |
Why?
|
| Hepatitis B | 6 | 2023 | 160 | 1.700 |
Why?
|
| Incidence | 26 | 2024 | 3093 | 1.560 |
Why?
|
| alpha-Fetoproteins | 16 | 2024 | 132 | 1.520 |
Why?
|
| Critical Pathways | 3 | 2025 | 77 | 1.480 |
Why?
|
| Cohort Studies | 34 | 2024 | 4751 | 1.460 |
Why?
|
| Gastrointestinal Hemorrhage | 6 | 2021 | 224 | 1.450 |
Why?
|
| Decision Support Techniques | 6 | 2021 | 290 | 1.420 |
Why?
|
| Quality of Health Care | 5 | 2014 | 391 | 1.410 |
Why?
|
| Health Care Costs | 7 | 2024 | 370 | 1.380 |
Why?
|
| Prevalence | 23 | 2024 | 2442 | 1.360 |
Why?
|
| International Classification of Diseases | 4 | 2024 | 90 | 1.340 |
Why?
|
| Adult | 68 | 2024 | 29395 | 1.320 |
Why?
|
| Health Services Accessibility | 4 | 2023 | 606 | 1.310 |
Why?
|
| Cost-Benefit Analysis | 13 | 2022 | 511 | 1.250 |
Why?
|
| Adenocarcinoma | 4 | 2023 | 998 | 1.250 |
Why?
|
| Alanine Transaminase | 8 | 2024 | 152 | 1.200 |
Why?
|
| Models, Theoretical | 8 | 2019 | 358 | 1.160 |
Why?
|
| Hospitals, Veterans | 7 | 2019 | 359 | 1.140 |
Why?
|
| Patient Admission | 2 | 2019 | 186 | 1.140 |
Why?
|
| Palliative Care | 6 | 2022 | 431 | 1.090 |
Why?
|
| Health Services Research | 5 | 2018 | 188 | 1.090 |
Why?
|
| Proportional Hazards Models | 11 | 2024 | 1327 | 1.040 |
Why?
|
| Sustained Virologic Response | 10 | 2023 | 41 | 1.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 5 | 2024 | 1251 | 1.030 |
Why?
|
| Societies, Medical | 3 | 2019 | 687 | 1.020 |
Why?
|
| Alcohol Drinking | 5 | 2024 | 340 | 1.010 |
Why?
|
| Quality Improvement | 3 | 2022 | 636 | 1.010 |
Why?
|
| Hemochromatosis | 2 | 2022 | 32 | 0.990 |
Why?
|
| Quality of Life | 11 | 2022 | 1944 | 0.970 |
Why?
|
| Benzofurans | 3 | 2022 | 24 | 0.960 |
Why?
|
| Age Factors | 14 | 2020 | 2810 | 0.960 |
Why?
|
| Quinoxalines | 3 | 2022 | 39 | 0.960 |
Why?
|
| Prognosis | 20 | 2024 | 4572 | 0.940 |
Why?
|
| Severity of Illness Index | 15 | 2023 | 2896 | 0.940 |
Why?
|
| Periodicals as Topic | 3 | 2017 | 195 | 0.930 |
Why?
|
| Aged, 80 and over | 23 | 2022 | 6484 | 0.920 |
Why?
|
| Patient Readmission | 2 | 2019 | 383 | 0.890 |
Why?
|
| Comorbidity | 10 | 2023 | 1527 | 0.890 |
Why?
|
| Imidazoles | 3 | 2022 | 193 | 0.880 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2016 | 241 | 0.880 |
Why?
|
| Ascites | 4 | 2023 | 88 | 0.870 |
Why?
|
| Treatment Outcome | 30 | 2022 | 12315 | 0.860 |
Why?
|
| Delphi Technique | 12 | 2024 | 210 | 0.860 |
Why?
|
| Interleukins | 2 | 2015 | 120 | 0.860 |
Why?
|
| Waiting Lists | 7 | 2024 | 228 | 0.850 |
Why?
|
| Algorithms | 10 | 2020 | 1614 | 0.830 |
Why?
|
| Proline | 2 | 2014 | 77 | 0.810 |
Why?
|
| Oligopeptides | 2 | 2014 | 117 | 0.810 |
Why?
|
| Databases, Factual | 7 | 2022 | 1178 | 0.810 |
Why?
|
| Genotype | 12 | 2023 | 2551 | 0.800 |
Why?
|
| Prospective Studies | 18 | 2024 | 6082 | 0.800 |
Why?
|
| Bile Acids and Salts | 1 | 2024 | 245 | 0.790 |
Why?
|
| Metabolic Diseases | 1 | 2023 | 129 | 0.780 |
Why?
|
| Metabolic Syndrome | 4 | 2022 | 332 | 0.780 |
Why?
|
| Disease Management | 2 | 2018 | 521 | 0.770 |
Why?
|
| Referral and Consultation | 5 | 2025 | 539 | 0.770 |
Why?
|
| Health Equity | 1 | 2023 | 57 | 0.760 |
Why?
|
| Veterans Health | 3 | 2018 | 176 | 0.740 |
Why?
|
| Biomedical Research | 4 | 2021 | 519 | 0.740 |
Why?
|
| Hypernatremia | 1 | 2021 | 29 | 0.730 |
Why?
|
| Drug Therapy, Combination | 9 | 2023 | 1158 | 0.720 |
Why?
|
| Digestive System Diseases | 2 | 2019 | 17 | 0.720 |
Why?
|
| Electronic Health Records | 5 | 2024 | 723 | 0.710 |
Why?
|
| Population Surveillance | 4 | 2021 | 389 | 0.710 |
Why?
|
| Peer Review | 1 | 2020 | 39 | 0.710 |
Why?
|
| Predictive Value of Tests | 12 | 2024 | 2127 | 0.710 |
Why?
|
| Hyponatremia | 1 | 2021 | 73 | 0.700 |
Why?
|
| Hospitalization | 4 | 2018 | 1775 | 0.690 |
Why?
|
| Awards and Prizes | 1 | 2021 | 64 | 0.690 |
Why?
|
| Patient-Centered Care | 3 | 2022 | 224 | 0.680 |
Why?
|
| Needs Assessment | 1 | 2021 | 175 | 0.680 |
Why?
|
| Disease Progression | 9 | 2024 | 2040 | 0.680 |
Why?
|
| Health Services Needs and Demand | 1 | 2021 | 174 | 0.670 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2020 | 75 | 0.670 |
Why?
|
| Metformin | 1 | 2021 | 148 | 0.670 |
Why?
|
| Gastrointestinal Microbiome | 7 | 2023 | 691 | 0.660 |
Why?
|
| Consensus | 8 | 2024 | 634 | 0.650 |
Why?
|
| Sodium | 4 | 2021 | 295 | 0.650 |
Why?
|
| Nutrition Surveys | 4 | 2019 | 291 | 0.640 |
Why?
|
| Coinfection | 5 | 2023 | 172 | 0.630 |
Why?
|
| Global Health | 2 | 2021 | 558 | 0.630 |
Why?
|
| Mortality | 2 | 2020 | 233 | 0.630 |
Why?
|
| Ultrasonography | 6 | 2024 | 929 | 0.620 |
Why?
|
| Obesity | 10 | 2024 | 2267 | 0.620 |
Why?
|
| Reimbursement Mechanisms | 1 | 2019 | 36 | 0.620 |
Why?
|
| Awareness | 1 | 2019 | 80 | 0.610 |
Why?
|
| Opioid-Related Disorders | 1 | 2022 | 261 | 0.610 |
Why?
|
| Health Services Administration | 1 | 2018 | 11 | 0.610 |
Why?
|
| Patient Discharge | 2 | 2019 | 496 | 0.600 |
Why?
|
| Time Factors | 13 | 2021 | 6285 | 0.590 |
Why?
|
| Pancreatitis | 1 | 2019 | 130 | 0.580 |
Why?
|
| Machine Learning | 1 | 2020 | 242 | 0.580 |
Why?
|
| Diabetes Complications | 2 | 2020 | 198 | 0.580 |
Why?
|
| Anniversaries and Special Events | 1 | 2017 | 12 | 0.580 |
Why?
|
| Review Literature as Topic | 2 | 2019 | 44 | 0.560 |
Why?
|
| Data Mining | 1 | 2017 | 54 | 0.550 |
Why?
|
| Australia | 3 | 2021 | 139 | 0.550 |
Why?
|
| Dyslipidemias | 2 | 2020 | 227 | 0.550 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2023 | 1126 | 0.550 |
Why?
|
| Gastrointestinal Diseases | 2 | 2017 | 330 | 0.550 |
Why?
|
| Natural Language Processing | 1 | 2017 | 63 | 0.550 |
Why?
|
| Primary Prevention | 2 | 2016 | 167 | 0.540 |
Why?
|
| Guideline Adherence | 4 | 2014 | 380 | 0.530 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2017 | 46 | 0.530 |
Why?
|
| Interferons | 4 | 2025 | 123 | 0.530 |
Why?
|
| Acute Kidney Injury | 2 | 2023 | 630 | 0.530 |
Why?
|
| Mouth Neoplasms | 1 | 2017 | 83 | 0.520 |
Why?
|
| Intestinal Mucosa | 5 | 2023 | 775 | 0.520 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2011 | 306 | 0.520 |
Why?
|
| Patient Compliance | 1 | 2019 | 472 | 0.520 |
Why?
|
| Survival Analysis | 7 | 2019 | 1490 | 0.520 |
Why?
|
| Malnutrition | 1 | 2019 | 204 | 0.510 |
Why?
|
| Practice Guidelines as Topic | 4 | 2019 | 1261 | 0.510 |
Why?
|
| Bile Duct Neoplasms | 1 | 2017 | 110 | 0.510 |
Why?
|
| Preventive Health Services | 2 | 2013 | 60 | 0.500 |
Why?
|
| Psychiatric Rehabilitation | 1 | 2015 | 5 | 0.500 |
Why?
|
| Trust | 1 | 2016 | 75 | 0.500 |
Why?
|
| Alcohol Abstinence | 1 | 2015 | 15 | 0.500 |
Why?
|
| HIV Infections | 4 | 2023 | 1891 | 0.500 |
Why?
|
| Patient Care Team | 2 | 2017 | 547 | 0.490 |
Why?
|
| Chronic Disease | 5 | 2023 | 1190 | 0.490 |
Why?
|
| Health Status | 4 | 2016 | 374 | 0.490 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2014 | 723 | 0.480 |
Why?
|
| Registries | 8 | 2020 | 1419 | 0.480 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2024 | 2089 | 0.470 |
Why?
|
| Reimbursement, Incentive | 1 | 2015 | 47 | 0.470 |
Why?
|
| Delivery of Health Care | 3 | 2023 | 606 | 0.470 |
Why?
|
| Carcinoma | 1 | 2017 | 280 | 0.470 |
Why?
|
| Thyroid Neoplasms | 1 | 2017 | 198 | 0.460 |
Why?
|
| Health Care Reform | 1 | 2014 | 50 | 0.460 |
Why?
|
| Self Report | 2 | 2017 | 520 | 0.460 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2018 | 598 | 0.450 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2014 | 18 | 0.450 |
Why?
|
| Colon | 4 | 2021 | 352 | 0.450 |
Why?
|
| Activities of Daily Living | 1 | 2016 | 404 | 0.450 |
Why?
|
| Liver Failure | 2 | 2005 | 89 | 0.440 |
Why?
|
| Diabetes Mellitus | 4 | 2016 | 859 | 0.440 |
Why?
|
| Infectious Disease Medicine | 1 | 2013 | 11 | 0.440 |
Why?
|
| Disease Eradication | 1 | 2014 | 32 | 0.430 |
Why?
|
| Young Adult | 14 | 2020 | 8970 | 0.430 |
Why?
|
| Hospital Mortality | 2 | 2017 | 1025 | 0.430 |
Why?
|
| Meta-Analysis as Topic | 2 | 2021 | 156 | 0.430 |
Why?
|
| Phospholipases A2, Calcium-Independent | 2 | 2024 | 13 | 0.430 |
Why?
|
| Quality Assurance, Health Care | 3 | 2010 | 206 | 0.430 |
Why?
|
| Hepatitis B virus | 6 | 2023 | 136 | 0.430 |
Why?
|
| Viremia | 6 | 2022 | 128 | 0.420 |
Why?
|
| Medicare | 5 | 2021 | 424 | 0.420 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2021 | 728 | 0.420 |
Why?
|
| Administration, Oral | 6 | 2019 | 678 | 0.420 |
Why?
|
| Health Planning Guidelines | 1 | 2013 | 32 | 0.420 |
Why?
|
| Liver | 7 | 2024 | 1760 | 0.420 |
Why?
|
| Alcoholism | 1 | 2015 | 231 | 0.420 |
Why?
|
| Patient Participation | 1 | 2015 | 221 | 0.420 |
Why?
|
| Behavior Therapy | 1 | 2015 | 257 | 0.410 |
Why?
|
| Depressive Disorder | 1 | 2016 | 456 | 0.410 |
Why?
|
| Kidney Neoplasms | 1 | 2017 | 429 | 0.410 |
Why?
|
| Bibliometrics | 1 | 2012 | 29 | 0.400 |
Why?
|
| Cross-Sectional Studies | 12 | 2023 | 3426 | 0.400 |
Why?
|
| Peer Review, Research | 1 | 2012 | 47 | 0.390 |
Why?
|
| Sex Factors | 6 | 2017 | 1277 | 0.390 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2024 | 3575 | 0.390 |
Why?
|
| Case-Control Studies | 6 | 2023 | 3269 | 0.390 |
Why?
|
| Cyclopropanes | 3 | 2022 | 68 | 0.380 |
Why?
|
| Polymorphism, Genetic | 1 | 2015 | 810 | 0.380 |
Why?
|
| Medical Records | 1 | 2012 | 191 | 0.380 |
Why?
|
| ROC Curve | 3 | 2021 | 563 | 0.370 |
Why?
|
| Asia | 2 | 2021 | 107 | 0.370 |
Why?
|
| Ambulatory Care Facilities | 1 | 2013 | 227 | 0.370 |
Why?
|
| Logistic Models | 9 | 2023 | 1807 | 0.350 |
Why?
|
| Europe | 2 | 2021 | 352 | 0.350 |
Why?
|
| Follow-Up Studies | 7 | 2019 | 5125 | 0.350 |
Why?
|
| Multivariate Analysis | 7 | 2016 | 1419 | 0.350 |
Why?
|
| Decision Making | 1 | 2015 | 654 | 0.350 |
Why?
|
| Risk | 4 | 2020 | 750 | 0.340 |
Why?
|
| Sulfonamides | 3 | 2022 | 263 | 0.340 |
Why?
|
| Proton Pump Inhibitors | 3 | 2009 | 261 | 0.330 |
Why?
|
| Surveys and Questionnaires | 7 | 2023 | 3724 | 0.330 |
Why?
|
| Organ Dysfunction Scores | 2 | 2020 | 48 | 0.330 |
Why?
|
| Biomarkers, Tumor | 4 | 2024 | 1460 | 0.330 |
Why?
|
| Catheter Ablation | 1 | 2012 | 238 | 0.330 |
Why?
|
| Biomarkers | 6 | 2024 | 2989 | 0.330 |
Why?
|
| Diet | 5 | 2023 | 1132 | 0.320 |
Why?
|
| Caffeine | 2 | 2023 | 70 | 0.320 |
Why?
|
| Attitude of Health Personnel | 1 | 2014 | 672 | 0.320 |
Why?
|
| Biopsy | 4 | 2020 | 1236 | 0.320 |
Why?
|
| History, 21st Century | 2 | 2021 | 269 | 0.320 |
Why?
|
| Tissue Donors | 6 | 2023 | 488 | 0.310 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2022 | 170 | 0.310 |
Why?
|
| Depression | 1 | 2017 | 1244 | 0.310 |
Why?
|
| Graft Survival | 8 | 2023 | 531 | 0.310 |
Why?
|
| Sensitivity and Specificity | 9 | 2024 | 2034 | 0.310 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2022 | 124 | 0.310 |
Why?
|
| History, 20th Century | 2 | 2021 | 384 | 0.300 |
Why?
|
| Texas | 6 | 2024 | 3588 | 0.300 |
Why?
|
| Heart Failure | 3 | 2018 | 2277 | 0.300 |
Why?
|
| Health Status Indicators | 1 | 2008 | 120 | 0.290 |
Why?
|
| Nutrition Assessment | 2 | 2019 | 136 | 0.290 |
Why?
|
| Dyspepsia | 2 | 2022 | 101 | 0.290 |
Why?
|
| Reproducibility of Results | 7 | 2024 | 2868 | 0.290 |
Why?
|
| Odds Ratio | 7 | 2016 | 1250 | 0.290 |
Why?
|
| Bacteria | 3 | 2022 | 484 | 0.280 |
Why?
|
| Patient Selection | 3 | 2020 | 693 | 0.280 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2009 | 264 | 0.280 |
Why?
|
| Demography | 2 | 2019 | 240 | 0.270 |
Why?
|
| Publishing | 2 | 2019 | 109 | 0.270 |
Why?
|
| Protein Precursors | 2 | 2024 | 152 | 0.270 |
Why?
|
| Colorectal Neoplasms | 2 | 2024 | 566 | 0.270 |
Why?
|
| Hepatitis B Vaccines | 3 | 2011 | 41 | 0.270 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2006 | 35 | 0.260 |
Why?
|
| Acyltransferases | 2 | 2024 | 44 | 0.260 |
Why?
|
| Gastric Mucosa | 1 | 2009 | 484 | 0.260 |
Why?
|
| Liver Cirrhosis, Alcoholic | 2 | 2023 | 36 | 0.260 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 61 | 0.260 |
Why?
|
| Hepatitis, Viral, Human | 2 | 2020 | 44 | 0.240 |
Why?
|
| Socioeconomic Factors | 3 | 2021 | 872 | 0.240 |
Why?
|
| Kidney Diseases | 1 | 2009 | 480 | 0.240 |
Why?
|
| Immunosuppressive Agents | 2 | 2021 | 644 | 0.230 |
Why?
|
| Adenine | 1 | 2005 | 101 | 0.230 |
Why?
|
| Glucagon-Like Peptide-2 Receptor | 1 | 2024 | 11 | 0.230 |
Why?
|
| Evidence-Based Medicine | 3 | 2021 | 631 | 0.230 |
Why?
|
| Gastric Inhibitory Polypeptide | 1 | 2024 | 19 | 0.230 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2024 | 25 | 0.230 |
Why?
|
| Sickness Impact Profile | 1 | 2004 | 36 | 0.230 |
Why?
|
| Pancreatitis, Chronic | 2 | 2015 | 68 | 0.230 |
Why?
|
| Republic of Korea | 1 | 2024 | 38 | 0.220 |
Why?
|
| Feeding Behavior | 2 | 2023 | 712 | 0.220 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2024 | 63 | 0.220 |
Why?
|
| Markov Chains | 3 | 2017 | 84 | 0.220 |
Why?
|
| Viral Load | 3 | 2012 | 384 | 0.210 |
Why?
|
| Serum Albumin | 2 | 2024 | 107 | 0.210 |
Why?
|
| Rectal Diseases | 1 | 2003 | 18 | 0.210 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 578 | 0.210 |
Why?
|
| Alcohol-Related Disorders | 1 | 2023 | 34 | 0.210 |
Why?
|
| RNA, Ribosomal, 16S | 5 | 2023 | 369 | 0.210 |
Why?
|
| Contraindications | 2 | 2013 | 78 | 0.210 |
Why?
|
| Models, Statistical | 2 | 2016 | 471 | 0.210 |
Why?
|
| Hepatic Encephalopathy | 1 | 2023 | 75 | 0.200 |
Why?
|
| Hemochromatosis Protein | 1 | 2022 | 22 | 0.200 |
Why?
|
| Trans Fatty Acids | 1 | 2022 | 10 | 0.200 |
Why?
|
| Albumins | 1 | 2022 | 88 | 0.200 |
Why?
|
| Lactams, Macrocyclic | 1 | 2022 | 18 | 0.200 |
Why?
|
| Ferritins | 1 | 2022 | 96 | 0.190 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2022 | 96 | 0.190 |
Why?
|
| Survival Rate | 2 | 2017 | 2028 | 0.190 |
Why?
|
| Carbamates | 2 | 2019 | 60 | 0.190 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2021 | 24 | 0.190 |
Why?
|
| Amides | 2 | 2019 | 84 | 0.190 |
Why?
|
| Ribavirin | 4 | 2023 | 80 | 0.190 |
Why?
|
| Tissue and Organ Procurement | 2 | 2020 | 219 | 0.190 |
Why?
|
| Clinical Coding | 1 | 2021 | 13 | 0.190 |
Why?
|
| Hepatitis, Alcoholic | 1 | 2021 | 26 | 0.180 |
Why?
|
| Health Care Rationing | 1 | 2021 | 58 | 0.180 |
Why?
|
| Postoperative Complications | 3 | 2018 | 3066 | 0.180 |
Why?
|
| Endoscopy, Gastrointestinal | 4 | 2014 | 243 | 0.180 |
Why?
|
| Patients | 1 | 2022 | 121 | 0.180 |
Why?
|
| Tooth Loss | 1 | 2020 | 4 | 0.180 |
Why?
|
| Hepatitis A Vaccines | 2 | 2010 | 10 | 0.180 |
Why?
|
| Platelet Count | 4 | 2024 | 136 | 0.180 |
Why?
|
| Hypoglycemic Agents | 1 | 2024 | 441 | 0.180 |
Why?
|
| Helicobacter pylori | 2 | 2022 | 1320 | 0.180 |
Why?
|
| Area Under Curve | 1 | 2021 | 316 | 0.180 |
Why?
|
| Colonoscopy | 1 | 2003 | 240 | 0.180 |
Why?
|
| Truth Disclosure | 1 | 2022 | 103 | 0.180 |
Why?
|
| Helicobacter Infections | 2 | 2022 | 1263 | 0.180 |
Why?
|
| Cholagogues and Choleretics | 1 | 2020 | 25 | 0.180 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2020 | 37 | 0.180 |
Why?
|
| Periodontal Diseases | 1 | 2020 | 24 | 0.170 |
Why?
|
| Coffee | 2 | 2023 | 24 | 0.170 |
Why?
|
| Emergency Service, Hospital | 2 | 2024 | 1088 | 0.170 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2022 | 153 | 0.170 |
Why?
|
| Heterozygote | 1 | 2022 | 676 | 0.170 |
Why?
|
| Hepatolenticular Degeneration | 1 | 2020 | 36 | 0.170 |
Why?
|
| Overweight | 1 | 2023 | 363 | 0.170 |
Why?
|
| Gastrointestinal Tract | 1 | 2022 | 214 | 0.170 |
Why?
|
| Learning Curve | 1 | 2020 | 52 | 0.170 |
Why?
|
| Drug Prescriptions | 2 | 2012 | 221 | 0.170 |
Why?
|
| Hypertension | 2 | 2020 | 1289 | 0.170 |
Why?
|
| Telemedicine | 2 | 2023 | 438 | 0.170 |
Why?
|
| Prothrombin | 3 | 2024 | 25 | 0.170 |
Why?
|
| Libya | 1 | 2019 | 3 | 0.160 |
Why?
|
| Plant Lectins | 1 | 2019 | 5 | 0.160 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 267 | 0.160 |
Why?
|
| Cognition Disorders | 1 | 2003 | 553 | 0.160 |
Why?
|
| Hepatomegaly | 3 | 2023 | 21 | 0.160 |
Why?
|
| Porphyria Cutanea Tarda | 1 | 2019 | 6 | 0.160 |
Why?
|
| Cryoglobulinemia | 1 | 2019 | 10 | 0.160 |
Why?
|
| Taste Perception | 1 | 2019 | 5 | 0.160 |
Why?
|
| Lichen Planus | 1 | 2019 | 8 | 0.160 |
Why?
|
| Data Warehousing | 1 | 2019 | 5 | 0.160 |
Why?
|
| Patient Acuity | 1 | 2019 | 64 | 0.160 |
Why?
|
| Pakistan | 1 | 2019 | 77 | 0.160 |
Why?
|
| Transferrin | 1 | 2019 | 51 | 0.160 |
Why?
|
| Prealbumin | 1 | 2019 | 27 | 0.160 |
Why?
|
| Appetite | 1 | 2019 | 37 | 0.160 |
Why?
|
| Graft Rejection | 2 | 2020 | 590 | 0.160 |
Why?
|
| Coronary Artery Disease | 2 | 2016 | 760 | 0.160 |
Why?
|
| Malabsorption Syndromes | 1 | 2019 | 36 | 0.160 |
Why?
|
| Glomerulonephritis | 1 | 2019 | 73 | 0.150 |
Why?
|
| Olfactory Perception | 1 | 2019 | 27 | 0.150 |
Why?
|
| Medicaid | 2 | 2019 | 243 | 0.150 |
Why?
|
| Terminal Care | 1 | 2020 | 112 | 0.150 |
Why?
|
| Aftercare | 1 | 2019 | 148 | 0.150 |
Why?
|
| Fluid Therapy | 1 | 2019 | 126 | 0.150 |
Why?
|
| Organ Transplantation | 1 | 2020 | 165 | 0.150 |
Why?
|
| Liver Function Tests | 2 | 2015 | 101 | 0.150 |
Why?
|
| Neoplasm Staging | 2 | 2024 | 1218 | 0.150 |
Why?
|
| Chemoprevention | 1 | 2018 | 57 | 0.150 |
Why?
|
| Endoscopy, Digestive System | 1 | 2019 | 153 | 0.150 |
Why?
|
| Drug Resistance, Viral | 2 | 2023 | 44 | 0.150 |
Why?
|
| Hospice Care | 1 | 2018 | 30 | 0.150 |
Why?
|
| Ulcer | 3 | 2009 | 48 | 0.150 |
Why?
|
| Ethanol | 3 | 2023 | 163 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 1020 | 0.140 |
Why?
|
| Transplant Recipients | 4 | 2021 | 216 | 0.140 |
Why?
|
| Propensity Score | 2 | 2016 | 212 | 0.140 |
Why?
|
| Bile Ducts, Extrahepatic | 1 | 2017 | 14 | 0.140 |
Why?
|
| Protective Factors | 1 | 2017 | 85 | 0.140 |
Why?
|
| Qualitative Research | 2 | 2022 | 548 | 0.140 |
Why?
|
| Electric Impedance | 1 | 2017 | 57 | 0.140 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2018 | 117 | 0.140 |
Why?
|
| Editorial Policies | 1 | 2017 | 53 | 0.140 |
Why?
|
| Health Personnel | 1 | 2022 | 505 | 0.140 |
Why?
|
| Journal Impact Factor | 1 | 2016 | 22 | 0.140 |
Why?
|
| Leadership | 1 | 2019 | 228 | 0.130 |
Why?
|
| Resuscitation | 1 | 2019 | 246 | 0.130 |
Why?
|
| Nutritional Status | 1 | 2019 | 312 | 0.130 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2017 | 95 | 0.130 |
Why?
|
| Recurrence | 2 | 2019 | 1423 | 0.130 |
Why?
|
| Nadolol | 1 | 2016 | 28 | 0.130 |
Why?
|
| Anthropometry | 1 | 2017 | 198 | 0.130 |
Why?
|
| Insulin | 1 | 2021 | 1206 | 0.130 |
Why?
|
| Tumor Burden | 1 | 2017 | 228 | 0.130 |
Why?
|
| Feasibility Studies | 1 | 2019 | 762 | 0.130 |
Why?
|
| Medical History Taking | 1 | 2016 | 106 | 0.130 |
Why?
|
| Inflammation | 2 | 2020 | 1417 | 0.130 |
Why?
|
| Acculturation | 1 | 2016 | 68 | 0.130 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2016 | 78 | 0.130 |
Why?
|
| Propranolol | 1 | 2016 | 128 | 0.130 |
Why?
|
| RNA, Viral | 3 | 2023 | 539 | 0.130 |
Why?
|
| Allografts | 3 | 2021 | 192 | 0.130 |
Why?
|
| Inappropriate Prescribing | 1 | 2015 | 41 | 0.120 |
Why?
|
| Health Services | 1 | 2016 | 71 | 0.120 |
Why?
|
| Microbiota | 1 | 2020 | 390 | 0.120 |
Why?
|
| Privacy | 1 | 2015 | 26 | 0.120 |
Why?
|
| Uridine Monophosphate | 1 | 2015 | 8 | 0.120 |
Why?
|
| Fluorenes | 1 | 2015 | 7 | 0.120 |
Why?
|
| Interferon-alpha | 4 | 2015 | 221 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 359 | 0.120 |
Why?
|
| Mexican Americans | 1 | 2016 | 204 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 375 | 0.120 |
Why?
|
| Social Stigma | 1 | 2015 | 74 | 0.120 |
Why?
|
| Treatment Refusal | 1 | 2015 | 77 | 0.120 |
Why?
|
| Adolescent | 7 | 2020 | 19301 | 0.120 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 422 | 0.120 |
Why?
|
| Health Surveys | 2 | 2007 | 244 | 0.120 |
Why?
|
| Jaundice | 1 | 2014 | 27 | 0.120 |
Why?
|
| Drug Costs | 1 | 2015 | 60 | 0.120 |
Why?
|
| Vietnam Conflict | 1 | 2014 | 9 | 0.120 |
Why?
|
| Hepatitis B Surface Antigens | 2 | 2023 | 52 | 0.120 |
Why?
|
| Ligation | 1 | 2014 | 135 | 0.110 |
Why?
|
| Cause of Death | 1 | 2016 | 470 | 0.110 |
Why?
|
| Pancreatitis, Acute Necrotizing | 1 | 2014 | 4 | 0.110 |
Why?
|
| Interviews as Topic | 1 | 2015 | 377 | 0.110 |
Why?
|
| Adipose Tissue | 1 | 2017 | 469 | 0.110 |
Why?
|
| Benzimidazoles | 1 | 2015 | 133 | 0.110 |
Why?
|
| SEER Program | 2 | 2020 | 200 | 0.110 |
Why?
|
| Body Mass Index | 2 | 2024 | 1556 | 0.110 |
Why?
|
| Caregivers | 1 | 2019 | 578 | 0.110 |
Why?
|
| Heart Rate | 1 | 2016 | 592 | 0.110 |
Why?
|
| Hypertension, Portal | 1 | 2014 | 78 | 0.110 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2014 | 108 | 0.110 |
Why?
|
| Liver Failure, Acute | 1 | 2014 | 89 | 0.110 |
Why?
|
| Appointments and Schedules | 1 | 2013 | 49 | 0.110 |
Why?
|
| Social Support | 1 | 2015 | 347 | 0.110 |
Why?
|
| Drug Therapy | 1 | 2013 | 85 | 0.100 |
Why?
|
| Length of Stay | 3 | 2021 | 1309 | 0.100 |
Why?
|
| Lipase | 2 | 2024 | 89 | 0.100 |
Why?
|
| Kidney | 1 | 2019 | 1348 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 1687 | 0.100 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 72 | 0.100 |
Why?
|
| Communication | 1 | 2016 | 515 | 0.100 |
Why?
|
| Gastric Lavage | 1 | 2011 | 2 | 0.100 |
Why?
|
| Gene Frequency | 1 | 2013 | 718 | 0.090 |
Why?
|
| Vitamin D | 1 | 2013 | 159 | 0.090 |
Why?
|
| Data Collection | 1 | 2013 | 383 | 0.090 |
Why?
|
| Linear Models | 1 | 2013 | 672 | 0.090 |
Why?
|
| Vaccination | 3 | 2011 | 953 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2019 | 721 | 0.090 |
Why?
|
| Outpatients | 1 | 2013 | 255 | 0.090 |
Why?
|
| Smoking | 1 | 2016 | 1037 | 0.090 |
Why?
|
| Benchmarking | 2 | 2022 | 134 | 0.090 |
Why?
|
| Statistics as Topic | 2 | 2008 | 254 | 0.090 |
Why?
|
| Health Policy | 1 | 2013 | 212 | 0.090 |
Why?
|
| Pandemics | 3 | 2023 | 1105 | 0.090 |
Why?
|
| Health Facilities | 1 | 2010 | 59 | 0.090 |
Why?
|
| Kidney Transplantation | 2 | 2005 | 637 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2025 | 1106 | 0.080 |
Why?
|
| Specialization | 1 | 2010 | 75 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2024 | 3138 | 0.080 |
Why?
|
| Insurance Coverage | 1 | 2011 | 121 | 0.080 |
Why?
|
| Stomach Ulcer | 1 | 2009 | 92 | 0.080 |
Why?
|
| Weight Loss | 2 | 2023 | 485 | 0.080 |
Why?
|
| Blood Transfusion | 1 | 2011 | 307 | 0.080 |
Why?
|
| Health Maintenance Organizations | 1 | 2008 | 22 | 0.080 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2017 | 112 | 0.080 |
Why?
|
| Inpatients | 1 | 2013 | 499 | 0.080 |
Why?
|
| Mutation | 1 | 2022 | 5805 | 0.080 |
Why?
|
| Viral Hepatitis Vaccines | 1 | 2008 | 20 | 0.080 |
Why?
|
| Preoperative Care | 2 | 2024 | 349 | 0.080 |
Why?
|
| Intestinal Diseases | 1 | 2009 | 84 | 0.080 |
Why?
|
| Immunization Programs | 1 | 2008 | 63 | 0.070 |
Why?
|
| Forecasting | 2 | 2020 | 351 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 2416 | 0.070 |
Why?
|
| Marital Status | 1 | 2007 | 33 | 0.070 |
Why?
|
| Decision Trees | 2 | 2006 | 49 | 0.070 |
Why?
|
| Psychological Tests | 1 | 2007 | 93 | 0.070 |
Why?
|
| Exercise | 2 | 2023 | 817 | 0.070 |
Why?
|
| Aspartate Aminotransferases | 2 | 2016 | 79 | 0.070 |
Why?
|
| Income | 1 | 2007 | 133 | 0.070 |
Why?
|
| Peptic Ulcer Hemorrhage | 1 | 2006 | 21 | 0.070 |
Why?
|
| Recombinant Proteins | 2 | 2011 | 1392 | 0.060 |
Why?
|
| Anti-Ulcer Agents | 1 | 2006 | 111 | 0.060 |
Why?
|
| Membrane Proteins | 2 | 2024 | 1529 | 0.060 |
Why?
|
| Arthritis | 1 | 2006 | 81 | 0.060 |
Why?
|
| Emigrants and Immigrants | 2 | 2022 | 145 | 0.060 |
Why?
|
| Hepatitis B e Antigens | 1 | 2005 | 13 | 0.060 |
Why?
|
| Pain | 1 | 2008 | 457 | 0.060 |
Why?
|
| Lamivudine | 1 | 2005 | 25 | 0.060 |
Why?
|
| Organophosphonates | 1 | 2005 | 19 | 0.060 |
Why?
|
| Somatoform Disorders | 1 | 2005 | 46 | 0.060 |
Why?
|
| Transaminases | 1 | 2005 | 33 | 0.060 |
Why?
|
| Clinical Trials, Phase IV as Topic | 1 | 2024 | 5 | 0.060 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2024 | 22 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 2613 | 0.060 |
Why?
|
| Health Resources | 1 | 2005 | 116 | 0.060 |
Why?
|
| Long-Term Care | 1 | 2004 | 70 | 0.060 |
Why?
|
| Mental Health | 1 | 2007 | 346 | 0.060 |
Why?
|
| Bilirubin | 1 | 2024 | 122 | 0.060 |
Why?
|
| Probability | 1 | 2004 | 323 | 0.060 |
Why?
|
| Fast Foods | 1 | 2023 | 35 | 0.050 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2003 | 19 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2005 | 194 | 0.050 |
Why?
|
| Policy | 1 | 2023 | 34 | 0.050 |
Why?
|
| Indians, North American | 1 | 2023 | 59 | 0.050 |
Why?
|
| Phospholipases | 1 | 2022 | 7 | 0.050 |
Why?
|
| Uvula | 1 | 2002 | 1 | 0.050 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2005 | 205 | 0.050 |
Why?
|
| Postoperative Period | 1 | 2003 | 333 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2023 | 88 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2023 | 400 | 0.050 |
Why?
|
| Adenosine Deaminase | 1 | 2022 | 74 | 0.050 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2022 | 49 | 0.050 |
Why?
|
| Tenofovir | 1 | 2022 | 16 | 0.050 |
Why?
|
| Secondary Prevention | 1 | 2023 | 216 | 0.050 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2024 | 127 | 0.050 |
Why?
|
| Integrases | 1 | 2023 | 161 | 0.050 |
Why?
|
| HIV | 1 | 2023 | 180 | 0.050 |
Why?
|
| Verrucomicrobia | 1 | 2021 | 14 | 0.050 |
Why?
|
| Neuropsychological Tests | 1 | 2005 | 925 | 0.050 |
Why?
|
| Kidney Failure, Chronic | 2 | 2005 | 877 | 0.050 |
Why?
|
| Tacrolimus | 1 | 2021 | 99 | 0.050 |
Why?
|
| Radiography | 1 | 2023 | 827 | 0.040 |
Why?
|
| Oral Health | 1 | 2020 | 17 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2004 | 1242 | 0.040 |
Why?
|
| Simvastatin | 1 | 2021 | 76 | 0.040 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2022 | 281 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2003 | 461 | 0.040 |
Why?
|
| Bacterial Load | 1 | 2020 | 29 | 0.040 |
Why?
|
| Diet, High-Fat | 1 | 2022 | 214 | 0.040 |
Why?
|
| Dietary Fats | 1 | 2022 | 298 | 0.040 |
Why?
|
| Vaccines, Synthetic | 1 | 2021 | 318 | 0.040 |
Why?
|
| Reference Standards | 1 | 2021 | 238 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2021 | 169 | 0.040 |
Why?
|
| Geography | 1 | 2020 | 110 | 0.040 |
Why?
|
| Fatty Acids | 1 | 2022 | 350 | 0.040 |
Why?
|
| Spain | 1 | 2019 | 60 | 0.040 |
Why?
|
| France | 1 | 2019 | 79 | 0.040 |
Why?
|
| Germany | 1 | 2019 | 66 | 0.040 |
Why?
|
| Food Analysis | 1 | 2019 | 26 | 0.040 |
Why?
|
| Italy | 1 | 2019 | 113 | 0.040 |
Why?
|
| Health Priorities | 1 | 2019 | 36 | 0.040 |
Why?
|
| Fibrosis | 1 | 2021 | 434 | 0.040 |
Why?
|
| Health Behavior | 1 | 2022 | 385 | 0.040 |
Why?
|
| United Kingdom | 1 | 2019 | 192 | 0.040 |
Why?
|
| Contrast Media | 1 | 2022 | 471 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2021 | 227 | 0.040 |
Why?
|
| Retreatment | 1 | 2018 | 88 | 0.040 |
Why?
|
| Feces | 1 | 2021 | 717 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2019 | 474 | 0.040 |
Why?
|
| Life Style | 1 | 2020 | 410 | 0.040 |
Why?
|
| Hepatitis C Antibodies | 2 | 2009 | 21 | 0.040 |
Why?
|
| Life Expectancy | 1 | 2017 | 53 | 0.030 |
Why?
|
| Remission Induction | 1 | 2018 | 301 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 287 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2019 | 333 | 0.030 |
Why?
|
| Work Schedule Tolerance | 1 | 2016 | 39 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2018 | 342 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2018 | 282 | 0.030 |
Why?
|
| Advance Care Planning | 1 | 2016 | 38 | 0.030 |
Why?
|
| Triglycerides | 1 | 2019 | 564 | 0.030 |
Why?
|
| Epidemiological Monitoring | 1 | 2016 | 59 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 1149 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 1400 | 0.030 |
Why?
|
| Patient-Specific Modeling | 1 | 2015 | 8 | 0.030 |
Why?
|
| Paris | 1 | 2015 | 10 | 0.030 |
Why?
|
| Sofosbuvir | 1 | 2015 | 14 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2021 | 2823 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2018 | 643 | 0.030 |
Why?
|
| Budgets | 1 | 2015 | 17 | 0.030 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2015 | 33 | 0.030 |
Why?
|
| Computational Biology | 1 | 2019 | 820 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2020 | 1761 | 0.030 |
Why?
|
| Diet Records | 1 | 2013 | 74 | 0.030 |
Why?
|
| Rheumatic Diseases | 1 | 2014 | 70 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2019 | 854 | 0.030 |
Why?
|
| Gastrointestinal Contents | 1 | 2011 | 12 | 0.020 |
Why?
|
| Hepatitis A Antibodies | 1 | 2010 | 9 | 0.020 |
Why?
|
| Hepatitis B Antibodies | 1 | 2010 | 24 | 0.020 |
Why?
|
| Lymphoma | 1 | 2014 | 321 | 0.020 |
Why?
|
| Medically Uninsured | 1 | 2011 | 73 | 0.020 |
Why?
|
| Mass Vaccination | 1 | 2010 | 12 | 0.020 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2010 | 39 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2011 | 138 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2011 | 223 | 0.020 |
Why?
|
| Drug Users | 1 | 2009 | 8 | 0.020 |
Why?
|
| Heart Diseases | 1 | 2014 | 490 | 0.020 |
Why?
|
| Prejudice | 1 | 2009 | 38 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 1892 | 0.020 |
Why?
|
| California | 1 | 2009 | 128 | 0.020 |
Why?
|
| Immunization Schedule | 1 | 2008 | 101 | 0.020 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2008 | 166 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2014 | 1017 | 0.020 |
Why?
|
| Atherosclerosis | 1 | 2014 | 849 | 0.020 |
Why?
|
| Models, Economic | 1 | 2006 | 51 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2006 | 95 | 0.020 |
Why?
|
| Office Visits | 1 | 2005 | 77 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2006 | 549 | 0.010 |
Why?
|
| Random Allocation | 1 | 2005 | 436 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2004 | 775 | 0.010 |
Why?
|
| Necrosis | 1 | 2002 | 206 | 0.010 |
Why?
|
| Research Design | 1 | 2005 | 690 | 0.010 |
Why?
|
| Animals | 1 | 2022 | 34157 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2005 | 1090 | 0.010 |
Why?
|
| Child | 1 | 2020 | 24439 | 0.010 |
Why?
|
| Ischemia | 1 | 2002 | 355 | 0.010 |
Why?
|